Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822355 | 0.87 | HTT (0.63) | MLYCDRAB9ALMNAHTTMAPK1 | |
| SCHEMBL29797355 | 0.87 | HTT (0.63) | MLYCDRAB9ALMNAHTTMAPK1 | |
| SCHEMBL760138 | 0.85 | MLYCD (0.43) | MLYCDRAB9ALMNAHTTMAPK1 | |
| SCHEMBL25218906 | 0.85 | MLYCD (0.50) | MLYCDRAB9ALMNAHTTMAPK1 | |
| SCHEMBL28411046 | 0.85 | TSHR (0.46) | MLYCDRAB9ALMNAHTTMAPK1 | |
| SCHEMBL2883042 | 0.85 | CES2 (0.52) | MLYCDRAB9ALMNAHTTMAPK1 | |
| SCHEMBL4568350 | 0.82 | MLYCD (0.49) | MLYCDRAB9ALMNAHTTMAPK1 | |
| SCHEMBL13664923 | 0.82 | CYP1A2 (0.45) | MLYCDRAB9ALMNAHTTCYP1A2 | |
| SCHEMBL760870 | 0.82 | MLYCD (0.49) | MLYCDLMNACYP1A2HSP90AA1HSP90AB1 | |
| SCHEMBL757232 | 0.82 | MLYCD (0.44) | MLYCDRAB9ALMNAHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9458170-B2 | Compound of camptothecin and preparation and use thereof | YULIANG LI (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862571-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | Li, Yuliang (MN) | 2015-04-22 | — | — | EP | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166559-A1 | COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF | TOP2A, TOP2B, TYMP | MLYCD 1887/4885RAB9A 1269/4885LMNA 472/4885 |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MLYCD 4608/4885RAB9A 1646/4885LMNA 4472/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | MLYCD 4780/4885RAB9A 1828/4885LMNA 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.